EVOLUTION OF THE UTILIZATION OF THE AIFA 5% FUND FOR ORPHAN DRUGS AND RARE DISEASES

被引：0
|
作者：
Tartarelli, F. [1 ]
Viola, V. [2 ]
Lidonnici, D. [3 ]
Marcellusi, A. [4 ]
机构：
[1] Sapienza Univ Roma, Rome, Italy
[2] Pharmavalue, Rome, Italy
[3] More Access Srl SB, Legnano, MI, Italy
[4] Univ Roma Tor Vergata, Fac Econ, Dept Econ & Finance, Econ Evaluat & HTA EEHTA CEIS, Rome, Italy
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HPR29
引用
收藏
页码：S259 / S259
页数：1
相关论文
共 50 条
  • [41] Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases
    Michaeli, J. C.
    Michaeli, C. T.
    Michaeli, D. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S927 - S928
  • [42] Orphan Drugs for Rare Diseases: Debating the Challenges of Health Commissioning in the UK
    Ticehurst, Flo
    JOURNAL OF MEDICAL GENETICS, 2008, 45 : S103 - S103
  • [43] CRITERIA TO DEFINE RARE DISEASES AND ORPHAN DRUGS: SYSTEMATIC LITERATURE REVIEW
    Abozaid, G.
    Kerr, K.
    McKnight, A.
    Al-Omar, H.
    VALUE IN HEALTH, 2022, 25 (12) : S264 - S264
  • [44] Balancing economic, ethical and equity concerns in orphan drugs and rare diseases
    McCabe, Christopher
    EJHP PRACTICE, 2010, 16 (04): : 22 - 25
  • [45] Criteria to define rare diseases and orphan drugs: a systematic review protocol
    Abozaid, Ghada Mohammed
    Kerr, Katie
    McKnight, Amy
    Al-Omar, Hussain A.
    BMJ OPEN, 2022, 12 (07):
  • [46] VALUE ASSESSMENT OF ORPHAN DRUGS FOR TREATMENT OF RARE DISEASES: A SYSTEMATIC REVIEW
    Lockhart, C. M.
    Hansen, R. N.
    VALUE IN HEALTH, 2016, 19 (03) : A79 - A79
  • [47] Ultra orphan drugs: the NHS model for managing extremely rare diseases
    Jessop, Edmund
    Upadhyaya, Sheela
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (12): : 1301 - 1308
  • [48] ORPHAN DRUGS TO TREATING RARE DISEASES: THE ITALIAN WAY FOR AN EARLY ACCESS
    Prada, M.
    Sansone, C.
    Bisagni, D.
    Mantovani, M.
    VALUE IN HEALTH, 2017, 20 (05) : A233 - A234
  • [49] Big Pharma's new model in orphan drugs and rare diseases
    Phillips, M. Ian
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (01): : 1 - 3
  • [50] Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review
    Kacetl, Jaroslav
    Maresova, Petra
    Maskuriy, Raihan
    Selamat, Ali
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2020, 13 : 2125 - 2148
12345